Diverse transcriptomic effects of evolved imipenem-relebactam resistance in Pseudomonas aeruginosa

Abstract

Imipenem-relebactam (Imi/Rel) is a {beta}-lactam/{beta}-lactamase inhibitor combination used for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. We previously reported that treatment-emergent resistance to Imi/Rel is associated with mutations in the AmpC beta-lactamase and/or the MexAB-OprM and MexEF-OprN efflux operons. However, the impact of these mutations on bacterial gene expression has not been explored extensively, particularly among P. aeruginosa from patients treated with Imi/Rel. To determine the effect of treatment-emergent Imi/Rel resistance on P. aeruginosa global transcription, we performed RNA sequencing on paired P. aeruginosa clinical isolates from six patients collected before and after Imi/Rel treatment. Transcriptional responses varied substantially, with no conserved changes in gene expression identified across all six patients. Three isolate pairs showed significant upregulation of previously characterized Imi/Rel resistance-associated genes in the treatment-emergent resistant isolate, while two resistant isolates displayed significant downregulation of ampC. Comparisons of the top 10 differentially regulated genes in the resistant isolate from each patient revealed only one gene that was shared between all six patients. Pathway enrichment analysis using Clusters of Orthologous Genes (COG) categories suggested that Imi/Rel exposure impacts transcription of genes involved in translation and metabolism, but these changes are highly variable between patients and isolates. Overall, we find that the transcriptional response of clinical P. aeruginosa to Imi/Rel exposure appears to be highly diverse and likely dependent on the genetic background of the infecting P. aeruginosa strain.

Disruption of arn lipid A aminoarabinosylation confers AmpCmediated cephalosporin resistance in Pseudomonas aeruginosa
Madeleine T. Hardie Boys, Samuel J. T. Wardell, Daniel Pletzer
Communications Biology2 Nov 2026Peer-reviewedCC BY 4.0General biologyNatureCrossref
pH-Dependent Evolution of Delafloxacin and Ciprofloxacin Resistance in Pseudomonas aeruginosa from cystic fibrosis (CF) and non-CF-patients
N. Ireddy, A. Bosch, H. Seth-Smith +2
bioRxiv8 Sep 2026PreprintAll rights reservedFull textMicrobiologybioRxiv
Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study
Katherine Young, C. Andrew DeRyke, David W. Hilbert +4
PLOS One15 Sep 2026Peer-reviewedCC BY 4.0MicrobiologyPLOS
Robust Inference of Phage Host Infection Dynamics from Sparse Single-Cell Transcriptomic Profiles in Pseudomonas aeruginosa
H. T. Wilms, J. Gurney
bioRxiv24 Sep 2026PreprintCC BY-NCFull textMicrobiologybioRxiv
Environment-mediated metabolic constraints shape antimicrobial resistance evolution in Pseudomonas aeruginosa
J. Ficarrotta, J. A. Papin, G. L. Kolling
bioRxiv19 Oct 2026PreprintCC BYFull textMicrobiologybioRxiv

Cite

BibTeX RIS

BibTeX

@misc{supandy2026diverse,
  title = {{Diverse transcriptomic effects of evolved imipenem-relebactam resistance in Pseudomonas aeruginosa}},
  author = {A. Supandy and A. J. Dorazio and K. M. Squires and E. G. Kline and R. K. Shields and D. Van Tyne},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.12.751187},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.12.751187v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - UNPB
TI  - Diverse transcriptomic effects of evolved imipenem-relebactam resistance in Pseudomonas aeruginosa
AU  - A. Supandy
AU  - A. J. Dorazio
AU  - K. M. Squires
AU  - E. G. Kline
AU  - R. K. Shields
AU  - D. Van Tyne
PY  - 2026
DA  - 2026/09/12
PB  - bioRxiv
DO  - 10.64898/2026.09.12.751187
UR  - https://www.biorxiv.org/content/10.64898/2026.09.12.751187v1
AB  - Imipenem-relebactam (Imi/Rel) is a {beta}-lactam/{beta}-lactamase inhibitor combination used for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. We previously reported that treatment-emergent resistance to Imi/Rel is associated with mutations in the AmpC beta-lactamase and/or the MexAB-OprM and MexEF-OprN efflux operons. However, the impact of these mutations on bacterial gene expression has not been explored extensively, particularly among P. aeruginosa from patients treated with Imi/Rel. To determine the effect of treatment-emergent Imi/Rel resistance on P. aeruginosa global transcription, we performed RNA sequencing on paired P. aeruginosa clinical isolates from six patients collected before and after Imi/Rel treatment. Transcriptional responses varied substantially, with no conserved changes in gene expression identified across all six patients. Three isolate pairs showed significant upregulation of previously characterized Imi/Rel resistance-associated genes in the treatment-emergent resistant isolate, while two resistant isolates displayed significant downregulation of ampC. Comparisons of the top 10 differentially regulated genes in the resistant isolate from each patient revealed only one gene that was shared between all six patients. Pathway enrichment analysis using Clusters of Orthologous Genes (COG) categories suggested that Imi/Rel exposure impacts transcription of genes involved in translation and metabolism, but these changes are highly variable between patients and isolates. Overall, we find that the transcriptional response of clinical P. aeruginosa to Imi/Rel exposure appears to be highly diverse and likely dependent on the genetic background of the infecting P. aeruginosa strain.
ER  -

Abstract

Related

Cite